WO1998040390A2 - Oligosaccharides et leurs derives et procede chimio-enzymatique permettant de les preparer - Google Patents
Oligosaccharides et leurs derives et procede chimio-enzymatique permettant de les preparer Download PDFInfo
- Publication number
- WO1998040390A2 WO1998040390A2 PCT/EP1998/001096 EP9801096W WO9840390A2 WO 1998040390 A2 WO1998040390 A2 WO 1998040390A2 EP 9801096 W EP9801096 W EP 9801096W WO 9840390 A2 WO9840390 A2 WO 9840390A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aav
- acetyl
- formula
- glucopyranosyl
- nmr
- Prior art date
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 26
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 title abstract description 9
- 238000006911 enzymatic reaction Methods 0.000 title description 4
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 claims abstract description 47
- 150000001299 aldehydes Chemical class 0.000 claims abstract description 42
- 238000006243 chemical reaction Methods 0.000 claims abstract description 37
- 229930182470 glycoside Natural products 0.000 claims abstract description 15
- 150000002338 glycosides Chemical class 0.000 claims abstract description 12
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 claims abstract description 7
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 claims abstract description 7
- -1 hydroxy, hydroxymethyl Chemical group 0.000 claims description 111
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 27
- 230000008569 process Effects 0.000 claims description 21
- 235000000346 sugar Nutrition 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 229910019142 PO4 Chemical group 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 239000010452 phosphate Chemical group 0.000 claims description 9
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims description 6
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 125000003051 glycosyloxy group Chemical group 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 5
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 5
- 125000004983 dialkoxyalkyl group Chemical group 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 238000007363 ring formation reaction Methods 0.000 claims description 4
- 238000005575 aldol reaction Methods 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 125000000468 ketone group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- 239000012434 nucleophilic reagent Substances 0.000 claims description 2
- 125000002524 organometallic group Chemical group 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 238000010561 standard procedure Methods 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 108090000072 Aldehyde-Lyases Proteins 0.000 abstract description 13
- 102000003677 Aldehyde-Lyases Human genes 0.000 abstract description 13
- 150000001720 carbohydrates Chemical class 0.000 abstract description 11
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 abstract description 10
- 230000002255 enzymatic effect Effects 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 8
- 239000012038 nucleophile Substances 0.000 abstract description 5
- 239000002243 precursor Substances 0.000 abstract description 5
- 239000000470 constituent Substances 0.000 abstract description 4
- 230000000707 stereoselective effect Effects 0.000 abstract description 4
- 230000001419 dependent effect Effects 0.000 abstract description 3
- 150000003014 phosphoric acid esters Chemical class 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract 1
- 238000007429 general method Methods 0.000 abstract 1
- 125000001553 ketosyl group Chemical group 0.000 abstract 1
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 abstract 1
- 241000702421 Dependoparvovirus Species 0.000 description 247
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 70
- 239000000203 mixture Substances 0.000 description 51
- 239000000243 solution Substances 0.000 description 45
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 17
- CYAYKKUWALRRPA-RGDJUOJXSA-N [(2r,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-bromooxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@H](Br)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O CYAYKKUWALRRPA-RGDJUOJXSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 14
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 238000007792 addition Methods 0.000 description 11
- 0 C*(CCCC1)[C@@]1OCC=O Chemical compound C*(CCCC1)[C@@]1OCC=O 0.000 description 10
- WGCNASOHLSPBMP-UHFFFAOYSA-N Glycolaldehyde Chemical compound OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 9
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 9
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 9
- 150000002772 monosaccharides Chemical class 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- XLSMFKSTNGKWQX-UHFFFAOYSA-N hydroxyacetone Chemical compound CC(=O)CO XLSMFKSTNGKWQX-UHFFFAOYSA-N 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101150096822 Fuca1 gene Proteins 0.000 description 6
- 208000007976 Ketosis Diseases 0.000 description 6
- 150000001241 acetals Chemical group 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 125000002156 N-acetyl-beta-D-glucosaminyl group Chemical group C(C)(=O)N[C@H]1C(O[C@@H]([C@H]([C@@H]1O)O)CO)* 0.000 description 5
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 5
- 239000000386 donor Substances 0.000 description 5
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 238000005949 ozonolysis reaction Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229910052718 tin Inorganic materials 0.000 description 5
- CYAYKKUWALRRPA-UHFFFAOYSA-N (3,4,5-triacetyloxy-6-bromooxan-2-yl)methyl acetate Chemical compound CC(=O)OCC1OC(Br)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O CYAYKKUWALRRPA-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000000370 acceptor Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 229910052738 indium Inorganic materials 0.000 description 4
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- BYDRTKVGBRTTIT-UHFFFAOYSA-N 2-methylprop-2-en-1-ol Chemical compound CC(=C)CO BYDRTKVGBRTTIT-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 238000006668 aldol addition reaction Methods 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000002337 glycosamines Chemical class 0.000 description 3
- 238000005858 glycosidation reaction Methods 0.000 description 3
- 125000003147 glycosyl group Chemical group 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 150000002584 ketoses Chemical group 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- ITMIAZBRRZANGB-BYPYZUCNSA-N (2s)-but-3-ene-1,2-diol Chemical compound OC[C@@H](O)C=C ITMIAZBRRZANGB-BYPYZUCNSA-N 0.000 description 2
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
- QIQQWSQARNQPLP-UHFFFAOYSA-N 2-(diethoxymethyl)oxirane Chemical compound CCOC(OCC)C1CO1 QIQQWSQARNQPLP-UHFFFAOYSA-N 0.000 description 2
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930182473 O-glycoside Natural products 0.000 description 2
- 150000008444 O-glycosides Chemical class 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- NLFHLQWXGDPOME-DEZPWFOKSA-N [(2r,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-[(2r,3r,4s,5r,6r)-4,5-diacetyloxy-2-(acetyloxymethyl)-6-bromooxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@H](Br)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1O[C@@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 NLFHLQWXGDPOME-DEZPWFOKSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001323 aldoses Chemical class 0.000 description 2
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 125000001118 alkylidene group Chemical group 0.000 description 2
- 125000006319 alkynyl amino group Chemical group 0.000 description 2
- 238000005937 allylation reaction Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- ITMIAZBRRZANGB-UHFFFAOYSA-N but-3-ene-1,2-diol Chemical compound OCC(O)C=C ITMIAZBRRZANGB-UHFFFAOYSA-N 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- YHPFSSDMRBEYRJ-UHFFFAOYSA-N hydron;thiourea;bromide Chemical compound Br.NC(N)=S YHPFSSDMRBEYRJ-UHFFFAOYSA-N 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 2
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical class BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 2
- XJNKZTHFPGIJNS-QMGXLNLGSA-N (2r,3r,4s,5r,6r)-2-(hydroxymethyl)-6-prop-2-enoxyoxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OCC=C)[C@H](O)[C@@H](O)[C@H]1O XJNKZTHFPGIJNS-QMGXLNLGSA-N 0.000 description 1
- XJNKZTHFPGIJNS-NXRLNHOXSA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-prop-2-enoxyoxane-3,4,5-triol Chemical compound OC[C@H]1O[C@H](OCC=C)[C@H](O)[C@@H](O)[C@H]1O XJNKZTHFPGIJNS-NXRLNHOXSA-N 0.000 description 1
- XJNKZTHFPGIJNS-SYHAXYEDSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-prop-2-enoxyoxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OCC=C)[C@H](O)[C@@H](O)[C@@H]1O XJNKZTHFPGIJNS-SYHAXYEDSA-N 0.000 description 1
- XJNKZTHFPGIJNS-ZEBDFXRSSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-prop-2-enoxyoxane-3,4,5-triol Chemical compound OC[C@H]1O[C@H](OCC=C)[C@H](O)[C@@H](O)[C@@H]1O XJNKZTHFPGIJNS-ZEBDFXRSSA-N 0.000 description 1
- XJNKZTHFPGIJNS-DFTQBPQZSA-N (2r,3s,4s,5s,6s)-2-(hydroxymethyl)-6-prop-2-enoxyoxane-3,4,5-triol Chemical compound OC[C@H]1O[C@H](OCC=C)[C@@H](O)[C@@H](O)[C@@H]1O XJNKZTHFPGIJNS-DFTQBPQZSA-N 0.000 description 1
- RJPPRBMGVWEZRR-FYKVHUBJSA-N (3S,4R,5R)-1,3,4,5-tetrahydroxy-6-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-one Chemical compound OC[C@H]1O[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO)[C@H](O)[C@@H](O)[C@@H]1O RJPPRBMGVWEZRR-FYKVHUBJSA-N 0.000 description 1
- OHWCAVRRXKJCRB-WLDMJGECSA-N (3r,4s,5s,6r)-2-methoxy-6-methyloxane-3,4,5-triol Chemical compound COC1O[C@H](C)[C@@H](O)[C@H](O)[C@H]1O OHWCAVRRXKJCRB-WLDMJGECSA-N 0.000 description 1
- OWWMLFPVVKPREV-UHFFFAOYSA-N (4-hydroxy-3-oxobutyl)phosphonic acid Chemical compound OCC(=O)CCP(O)(O)=O OWWMLFPVVKPREV-UHFFFAOYSA-N 0.000 description 1
- HEVMDQBCAHEHDY-UHFFFAOYSA-N (Dimethoxymethyl)benzene Chemical compound COC(OC)C1=CC=CC=C1 HEVMDQBCAHEHDY-UHFFFAOYSA-N 0.000 description 1
- ORTVZLZNOYNASJ-UPHRSURJSA-N (z)-but-2-ene-1,4-diol Chemical compound OC\C=C/CO ORTVZLZNOYNASJ-UPHRSURJSA-N 0.000 description 1
- 150000000180 1,2-diols Chemical class 0.000 description 1
- LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- ULIKDJVNUXNQHS-UHFFFAOYSA-N 2-Propene-1-thiol Chemical compound SCC=C ULIKDJVNUXNQHS-UHFFFAOYSA-N 0.000 description 1
- JFFYKITVXPZLQS-UHFFFAOYSA-N 2-methylidenepropane-1,3-diol Chemical compound OCC(=C)CO JFFYKITVXPZLQS-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LVSQXDHWDCMMRJ-UHFFFAOYSA-N 4-hydroxybutan-2-one Chemical compound CC(=O)CCO LVSQXDHWDCMMRJ-UHFFFAOYSA-N 0.000 description 1
- BXBJZYXQHHPVGO-UHFFFAOYSA-N 4-hydroxycyclohexan-1-one Chemical compound OC1CCC(=O)CC1 BXBJZYXQHHPVGO-UHFFFAOYSA-N 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 229930191235 Aglykon Natural products 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229930182476 C-glycoside Natural products 0.000 description 1
- 150000000700 C-glycosides Chemical class 0.000 description 1
- NDXWGZXCMJDZEL-OYTUSDIESA-N C=CC(CO)OC(C(C1O)O)OC(CO)[C@@H]1O Chemical compound C=CC(CO)OC(C(C1O)O)OC(CO)[C@@H]1O NDXWGZXCMJDZEL-OYTUSDIESA-N 0.000 description 1
- IRUILVRDTWHENR-RDLLZXPWSA-N C=CC(CO)OCC(COC(CO)[C@H]1O[C@H](C(C2O)O)OC(CO)[C@H]2O)(C1O)O Chemical compound C=CC(CO)OCC(COC(CO)[C@H]1O[C@H](C(C2O)O)OC(CO)[C@H]2O)(C1O)O IRUILVRDTWHENR-RDLLZXPWSA-N 0.000 description 1
- NDXWGZXCMJDZEL-LULBFSCDSA-N C=CC(CO)O[C@@H](C(C1O)O)OC(CO)[C@H]1O Chemical compound C=CC(CO)O[C@@H](C(C1O)O)OC(CO)[C@H]1O NDXWGZXCMJDZEL-LULBFSCDSA-N 0.000 description 1
- RCPIOJHHYYNWDP-UHFFFAOYSA-N C=CCC(C(C1O)O)OCC1O Chemical compound C=CCC(C(C1O)O)OCC1O RCPIOJHHYYNWDP-UHFFFAOYSA-N 0.000 description 1
- RCPIOJHHYYNWDP-LHZZQDSXSA-N C=CC[C@@H](C(C1O)O)OC[C@@H]1O Chemical compound C=CC[C@@H](C(C1O)O)OC[C@@H]1O RCPIOJHHYYNWDP-LHZZQDSXSA-N 0.000 description 1
- RCPIOJHHYYNWDP-MOMMNUENSA-N C=CC[C@@H](C([C@@H]1O)O)OC[C@H]1O Chemical compound C=CC[C@@H](C([C@@H]1O)O)OC[C@H]1O RCPIOJHHYYNWDP-MOMMNUENSA-N 0.000 description 1
- RCPIOJHHYYNWDP-QQJWGCFSSA-N C=CC[C@H](C(C1O)O)OCC1O Chemical compound C=CC[C@H](C(C1O)O)OCC1O RCPIOJHHYYNWDP-QQJWGCFSSA-N 0.000 description 1
- RCPIOJHHYYNWDP-INFAEJQFSA-N C=CC[C@H](C(C1O)O)OC[C@H]1O Chemical compound C=CC[C@H](C(C1O)O)OC[C@H]1O RCPIOJHHYYNWDP-INFAEJQFSA-N 0.000 description 1
- FMOOVWQVVNJBPZ-GYBMRGMWSA-N C=C[C@@H](COC(C([C@H]1O)O)OC(CO)[C@H]1O)O[C@@H](C(C1O)O)OC(CO)[C@H]1O Chemical compound C=C[C@@H](COC(C([C@H]1O)O)OC(CO)[C@H]1O)O[C@@H](C(C1O)O)OC(CO)[C@H]1O FMOOVWQVVNJBPZ-GYBMRGMWSA-N 0.000 description 1
- JIMWXFWXOSWLSG-ITSPCKDYSA-N C=C[C@@H](CO[C@@H](C(C1O)O)OC(CO)C1O)O Chemical compound C=C[C@@H](CO[C@@H](C(C1O)O)OC(CO)C1O)O JIMWXFWXOSWLSG-ITSPCKDYSA-N 0.000 description 1
- JNDAMLBGNAAATJ-NBQXLRJMSA-N CC(N(CC=C)[C@@H](C(C1O)O)O[C@H](CO)[C@H]1O)=O Chemical compound CC(N(CC=C)[C@@H](C(C1O)O)O[C@H](CO)[C@H]1O)=O JNDAMLBGNAAATJ-NBQXLRJMSA-N 0.000 description 1
- XDCPCOUHVRDOEN-ZFDXQJORSA-N CC([C@@H](C1O)O)O[C@@H](CC=C)C1O Chemical compound CC([C@@H](C1O)O)O[C@@H](CC=C)C1O XDCPCOUHVRDOEN-ZFDXQJORSA-N 0.000 description 1
- JEMFGBFLGLMZGN-XSRCVXOTSA-N CC([C@H]([C@@H](C1)O)O)O[C@@H]1N(CC=C)C(C)=O Chemical compound CC([C@H]([C@@H](C1)O)O)O[C@@H]1N(CC=C)C(C)=O JEMFGBFLGLMZGN-XSRCVXOTSA-N 0.000 description 1
- YREVFCZSEWDGOB-YGTXGTAKSA-N CC1(C)OC(CC=C)(CO[C@@H](C(C2O)O)OC(CO)[C@H]2O)CO1 Chemical compound CC1(C)OC(CC=C)(CO[C@@H](C(C2O)O)OC(CO)[C@H]2O)CO1 YREVFCZSEWDGOB-YGTXGTAKSA-N 0.000 description 1
- RZFUBDMOKMZZAQ-UHFFFAOYSA-N CCOC(C(CSC(C(C1O)O)OC(C)C1O)O)OCC Chemical compound CCOC(C(CSC(C(C1O)O)OC(C)C1O)O)OCC RZFUBDMOKMZZAQ-UHFFFAOYSA-N 0.000 description 1
- BIRCLPXRMFRGSH-CSANVUMISA-N C[C@@](CO[C@@H](C([C@H]1O)O)OC(CO)[C@H]1O)(C=C)O[C@@H](C(C1O)O)OC(CO)[C@H]1O Chemical compound C[C@@](CO[C@@H](C([C@H]1O)O)OC(CO)[C@H]1O)(C=C)O[C@@H](C(C1O)O)OC(CO)[C@H]1O BIRCLPXRMFRGSH-CSANVUMISA-N 0.000 description 1
- MGBWIQXXMLUTOO-LWOQYNTDSA-N C[O]([C@H](CCC1)O)C1O Chemical compound C[O]([C@H](CCC1)O)C1O MGBWIQXXMLUTOO-LWOQYNTDSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- XPYBSIWDXQFNMH-UHFFFAOYSA-N D-fructose 1,6-bisphosphate Natural products OP(=O)(O)OCC(O)C(O)C(O)C(=O)COP(O)(O)=O XPYBSIWDXQFNMH-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 108010008604 L-alpha-glycerol-phosphate oxidase Proteins 0.000 description 1
- 108010012710 L-fuculose-phosphate aldolase Proteins 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100241859 Mus musculus Oacyl gene Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- CELWCAITJAEQNL-UHFFFAOYSA-N OC1OCCCC1 Chemical compound OC1OCCCC1 CELWCAITJAEQNL-UHFFFAOYSA-N 0.000 description 1
- IEDKAOBANDQOQU-UUBYXRMQSA-N OCC(C1O)OC(COC(C(C2O)O)OC[C@H]2O)C[C@H]1O Chemical compound OCC(C1O)OC(COC(C(C2O)O)OC[C@H]2O)C[C@H]1O IEDKAOBANDQOQU-UUBYXRMQSA-N 0.000 description 1
- CQORPHBLBZJUBR-HSBVKHSESA-N OCC([C@H](C(C1O)O)O)O[C@H]1OC(CC1)CCC1=O Chemical compound OCC([C@H](C(C1O)O)O)O[C@H]1OC(CC1)CCC1=O CQORPHBLBZJUBR-HSBVKHSESA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108030003267 Rhamnulose-1-phosphate aldolases Proteins 0.000 description 1
- 229930182475 S-glycoside Natural products 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000191965 Staphylococcus carnosus Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- OPVYKVGCFWDTOI-PLVISXMQSA-N [(2S,3S,4R,5R)-3,4,5-triacetyloxy-6-oxohexan-2-yl] acetate Chemical compound C(C)(=O)O[C@@H](C=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)C OPVYKVGCFWDTOI-PLVISXMQSA-N 0.000 description 1
- ZYPMNZKYVVSXOJ-UPJWGTAASA-N [(2r,3r,4s)-2,3,4-triacetyloxy-5-oxopentyl] acetate Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)C=O ZYPMNZKYVVSXOJ-UPJWGTAASA-N 0.000 description 1
- ZYPMNZKYVVSXOJ-YNEHKIRRSA-N [(2r,3s,4r)-2,3,4-triacetyloxy-5-oxopentyl] acetate Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)C=O ZYPMNZKYVVSXOJ-YNEHKIRRSA-N 0.000 description 1
- CRUHDGOVWKFJBM-DRRXZNNHSA-N [(2r,3s,4s,5r,6r)-3,4,5-triacetyloxy-6-prop-2-enoxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OCC=C)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O CRUHDGOVWKFJBM-DRRXZNNHSA-N 0.000 description 1
- NLFHLQWXGDPOME-KQGMPROSSA-N [(2r,3s,4s,5r,6s)-3,4,5-triacetyloxy-6-[(2r,3r,4s,5r)-4,5-diacetyloxy-2-(acetyloxymethyl)-6-bromooxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1OC(Br)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1O[C@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(C)=O)O1 NLFHLQWXGDPOME-KQGMPROSSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000005282 allenyl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001450 anions Chemical group 0.000 description 1
- 239000011013 aquamarine Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- RNBGYGVWRKECFJ-ARQDHWQXSA-N beta-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 150000008266 deoxy sugars Chemical class 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- SDIXRDNYIMOKSG-UHFFFAOYSA-L disodium methyl arsenate Chemical class [Na+].[Na+].C[As]([O-])([O-])=O SDIXRDNYIMOKSG-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 125000005640 glucopyranosyl group Chemical group 0.000 description 1
- 239000000937 glycosyl acceptor Substances 0.000 description 1
- 239000000348 glycosyl donor Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- BRKDRDWOZIWFFV-UHFFFAOYSA-N hydrogen carbonate;methylazanium Chemical compound [NH3+]C.OC([O-])=O BRKDRDWOZIWFFV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- CPJRRXSHAYUTGL-UHFFFAOYSA-N isopentenyl alcohol Chemical compound CC(=C)CCO CPJRRXSHAYUTGL-UHFFFAOYSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- FQGYCXFLEQVDJQ-UHFFFAOYSA-N mercury dicyanide Chemical compound N#C[Hg]C#N FQGYCXFLEQVDJQ-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- GMDGXJQUWIQOLE-UHFFFAOYSA-N prop-2-enylborane Chemical compound BCC=C GMDGXJQUWIQOLE-UHFFFAOYSA-N 0.000 description 1
- WLHPCEJPGLYEJZ-UHFFFAOYSA-N prop-2-enyltin Chemical compound [Sn]CC=C WLHPCEJPGLYEJZ-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003774 sulfhydryl reagent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000006098 transglycosylation Effects 0.000 description 1
- 238000005918 transglycosylation reaction Methods 0.000 description 1
- HYWCXWRMUZYRPH-UHFFFAOYSA-N trimethyl(prop-2-enyl)silane Chemical compound C[Si](C)(C)CC=C HYWCXWRMUZYRPH-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
Definitions
- Oli2osaccharides and their derivatives as well as a chemo-enzymatic process for their production
- the invention relates to new oligosaccharides and their derivatives and a general
- oligosaccharides which carry an additional ketose unit at the reducing end when DHAP-dependent aldolases are used, and their corresponding phosphate esters and suitable derivatives are of interest as components or precursors of active pharmaceutical ingredients.
- Oligosaccharides play an eminently important role as information carriers of high information density in many biological recognition processes such as Cell growth, differentiation, aggregation and migration. With innumerable human diseases, oligosaccharide-receptor interactions are of fundamental importance, e.g. in the case of immunological defense reactions, tumor diseases or infections by parasites, bacteria or viruses. Structures derived from oligosaccharides are therefore becoming increasingly interesting as potential pharmaceuticals to moderate or block biological communication channels - especially in clinical pictures such as acute or chronic inflammation, asthma, immunological diseases, tumor metastasis, transplant rejection, infectious diseases and cardiovascular diseases.
- the variation of Linking sites between building blocks requires the targeted provision of a free OH group on the acceptor and the protection of all other OH groups for chemical processes, g) the protective groups in the acceptor exerting a controlling influence on the reactivity of the acceptor OH group, h) the variation of the linkage on the anomeric C atom (diastereoselectivity with regard to the a / b configuration) must be controlled stereochemically by the decisive influence of the protective groups in the donor, i) additional kinetic and thermodynamic influences on the diastereoselectivity (anom rer effect) to be considered by the conduct of the reaction, what k) can be influenced by the type of activation of the anomeric center in the glycosyl donor by introducing a suitable escape group and choosing a catalytic promoter,
- Oligosaccharides made up of the naturally occurring monosaccharides are also unsuitable for therapeutic purposes because of their high biological metabolism rate
- the invention describes a broadly applicable process for the rapid, stereoselective generation of a large number of complex oligosaccharides and of metabolically stable non-natural derivatives from cheap or easily accessible starting materials. It has surprisingly been found that glycosylated aldehydes which, owing to their simple structure, can be compared with conventional ones Synthesis methodology are accessible conveniently and efficiently, by means of certain chemical and / or enzymatic methods for chain extension by means of CC linkage stereoselectively in one
- Saccharide unit to convert enlarged oligosaccharides, whereby elaborate protective group techniques can be largely avoided. If chirality centers are newly created, this procedure allows the controlled stereodivergent synthesis of a large number of diastereoisomers (2 n for n new centers) from the same aldehyde starting material.
- the invention relates to compounds of the general formula (I)
- A represents CH 2 or a radical of the formula
- B represents CH 2 , a bond or a radical of the formula
- R represents hydrogen or phosphate
- R 1 represents an optionally substituted glycosyl radical
- R 2 and R 3 may be the same or different and represent hydrogen, hydroxy, hydroxyalkyl, glycosyloxy, glycosyloxyalkyl, alkoxyalkyl, dialkoxyalkyl or
- 5- or 6-membered saturated ring which can contain up to 2 oxygen atoms, wherein the ring can be substituted up to twice by lower alkyl, and
- R 4 represents hydrogen, alkyl, alkyloxycarbonyl, carboxy or glycosyloxyalkyl,
- X represents -O-, -OCH 2 -, -N (alkanoyl) -, -S-, -SCH 2 - or a bond
- R 1 ' independently of R 1 , can have the meanings given for R 1 ,
- R 3 'independently of R 3 can have the meanings given for R 3 and
- X 'can have the meanings given for X independently of X.
- the compounds of formula (I) contain several stereocenters. They can therefore exist in stereoisomeric forms that either behave like images and mirror images (enantiomers) or that do not behave like images and mirror images (diastereomers).
- the invention relates to both the enantiomers and the diastereomers or their respective mixtures. Mixtures of the enantiomers or also of the diastereomers can be separated into the stereoisomerically uniform constituents in a known manner, for example by crystallization or chromatography processes.
- R 2 and R 3 can be the same or different and represent hydrogen, hydroxy
- R 4 represents hydrogen, methyl, methoxycarbonyl, carboxy or glycosyloxymethyl
- X represents -O-, -OCH 2 -, -N (acetyl) -, -S-, -SCH 2 - or a bond
- R 3 'independently of R 3 can have the meanings given for R 3 and
- X 'can have the meanings given for X independently of X.
- glycosyl residues and for the glycosyl residues in the "glycosyloxy" and “glycosyloxyalkyl” residues are erythro mattersanosyl, threo Divisionanosyl, ribo Solutionsanosyl, arabino Solutionsanosyl, xylo Solutionsanosyl, allofuranosyl, glucofuranosyl, manno Relationanosyl,
- Fructopyranosyl Altro-heptulo-pyranosyl, Glycero-manno-octulo-pyranosyl or Erythro-gluco-nonulo-pyranosyl, (Methyl-6-deoxy-glucopyranoside) -6-yl, (Methyl-3-deoxy-glucopyranoside) -3- yl or methyl-4-deoxy-glucopyranoside) -4-yl.
- hydroxyl groups in the glycosyl radicals can be replaced by other substituents, for example by hydrogen, lower alkyl, halogen, lower alkoxy, oxa-lower alkyloxy, lower alkenyloxy, cycloalkoxy, tetrahydropyranyloxy, arylalkyloxy, heteroarylalkyloxy, lower alkyloxy-arylalkyloxy, alkylidendioxl, lower alkoxydoyloxy, lower alkydoyloxy which is substituted by halogen, arylcarbonyloxy or
- Arylcarbonyloxy which is substituted by halogen or lower alkoxy, lower alkylsulfonyloxy, arylsulfonyloxy, lower alkylarylsulfonyloxy, oxo, amino, mono- or di-lower alkylamino, formylamino, lower alkanoylamino or lower alkanoylamino, which is substituted by halogen, lower alkynylamino, arylalkylthaloxy, azido Lower alkylthio
- Phosphonooxy dialkyloxy-phosphoryloxy, dibenzyloxyphosphoryloxy, sulfooxy, alkyloxysulfonyloxy, benzyloxysulfonyloxy or sulfamoyloxy, optionally substituted glycosyloxy or optionally substituted di- or
- glycosyl radicals in which one or more or all of the hydroxyl groups have been replaced or substituted are 2-amino-2-deoxy-glucopyranosyl, 2-amino-2-deoxy-galactopyranosyl, 2-acetylamino-2-deoxy- glucopyranosyl, 2-acetylamino-2-deoxy-galactopyranosyl, 2-azido-2-deoxy-glucopyranosyl, 2-deoxy-glucopyranosyl, 4-deoxy-glucopyranosyl, 6-chloro-6-deoxy-gluco- for anosyl, 6-deoxy-6-fluoro-glucopyranosyl, 4-chloro-4-deoxy-glucopyranosyl, gluco mattersanos-3-ulosyl, 6-thio-glucopyranosyl, 3-thio-galactoognianosyl, 5-acetylamino-3,5- dideoxy-g
- 6-O-phosphoryl-galactopyranosyl 2,3,4,6-tetra-O-methyl-glucopyranosyl, 2,3,4,6-tetra-O-acetyl-glucopyranosyl, 2,3,4,6-tetra- O-benzyl-glucopyranosyl, 2,3,4,6-tetra-O-benzyl-galactopyranosyl, 2,3,4,6-tetra-O-benzyl-mannopyranosyl, 2,3,4-tri-O-benzyl- rhamnopyranosyl, 2,3,4-tri-O-benzyl-fucyranosyl, 2,3-di-O-allyl-4,6-di-O-benzyl-mannopyranosyl, 2,3-di-O-acetyl-4, 6-O-benzylidene-glucopyranosyl,
- Alkyl as a separate substituent or as part of other radicals such as hydroxyalkyl, glycosyloxyalkyl, alkoxyalkyl, dialkoxyalkyl, alkoxy, alkanoyl means a straight-chain or branched alkyl radical having up to 8, preferably up to 6 and particularly preferably up to 4, carbon atoms.
- Lower alkyloxy means a straight-chain or branched alkyl radical having up to 7, preferably up to 5 and particularly preferably up to 3 carbon atoms.
- Lower alkenyl as a separate substituent or as part of other radicals such as, for example, lower alkenyloxy represents a straight-chain or branched alkene radical with up to
- Alkylidene as its own radical or as part of other radicals such as, for example, alkylidendioxy means a straight-chain or branched alkylidene chain having up to 8, preferably up to 6, particularly preferably up to 4, carbon atoms.
- Aryl as a separate substituent or as part of other radicals such as arylalkyloxy represents an aryl radical having up to 10, preferably up to 6, carbon atoms, for example phenyl.
- Alkynyl as a separate substituent or as part of other radicals such as
- Lower alkynylamino stands for a straight-chain or branched alkynyl radical having up to 8, preferably up to 6, particularly preferably up to 4 carbon atoms.
- the present invention relates to a process for the preparation of enantiomerically pure and diastereomerically pure oligosaccharides and their derivatives
- carbon nucleophiles for the second addition are dihydroxyacetone phosphate and a fructose-1,6-bisphosphataldolase ([EC 4.1.2.13]), tagatose-1,6-bisphosphataldolase ([EC 4.1.2]), fuculose-1-phosphataldolase ( [EC 4.1.2.17]) or rhamnulose-1-phosphataldolase ([EC 4.1.2.19]).
- the compounds of the formula (I) can generally be prepared from three key steps to be carried out consecutively.
- a schematic overview in Scheme 1 may clarify this without being restrictive
- a glycoside that contains a polar addition-capable double bond in the aglycon part typically an aldehyde, ketone or ester-carbonyl grouping or a synthesis equivalent familiar to the person skilled in the art, from which this function is used before the next reaction step can be easily generated.
- Such a suitable glycoside can e.g. are obtained by preparing compounds of the formula (IV) by known processes,
- R 1 , R 2 , R 3 , R 4 and X have the meanings given above and
- R 5 and R 6 can be the same or different and represent hydrogen, alkyl or aryl
- R 1 , R 2 , R 3 , R 4 and X have the meanings given above.
- a C-nucleophilic reagent with C-C linkage is added to this double bond, a heteronucleophile, which is typically an alcohol, being produced from the original double bond.
- the reagent must itself contain an aldehyde function in a masked form, e.g.
- R 1 , R 2 , R 3 , R 4 and X have the meanings given above and in the
- R 1 , R 2 , R 3 , R 4 and X have the meanings given above,
- a heteronucleophile can optionally also be contained directly in the aglycon part, whereupon the second step can then be omitted.
- step (2) can also be repeated several times in the sense of the invention
- the well-developed glycosidation processes according to Fischer or the numerous variants of the Konigs - &? Orr synthesis can be used (see the overviews above on the state of the art). nik)
- the glycosidic fraction can be selected according to its constitution and the glycosidic linkage.
- aldoses and ketoses typically with four to 8 carbon atoms in the chain
- those with a non-natural configuration or constitution for example Aza-, thia-, phospha- or carbazucker
- differently substituted for example O- or C-alkylated, O-acyherte, deoxy- or amino sugar
- oxidized (glyconic and glycuronic acids, ketoaldoses, dial cans, etc.) descendants can be used
- the part can be in its constitution (linear, branched, substituted), large (typically C2-C4), glycosidic linking position (typically alpha or beta to the aldehyde) and possibly its absolute
- the simplest and typical case here is the allyl glycosides, of which some are also commercially available.
- other aldehyde precursors can also be used, such as glycosylated acetals, alcohols, esters, carboxylic acids and other synthetic equivalents known to the person skilled in the art
- linkages can also be used for the process according to the invention, such as N-, S- or C-glycosides, the production of which is known to the person skilled in the art and which have a significantly higher metabolic stability compared to the O-glycosides exhibit
- the 1-O- and 2-O-glycosides of 3-butene-1,2-diol and compounds to be derived therefrom are also advantageous, since here the point of attachment in the glycosyl acceptor can be optionally determined and secondly the heteronucleophile for later ring formation.
- Butenediol is commercially available in both racemic and enantiomerically pure form.
- the allenyl adducts are formed in addition to the corresponding propargyl compounds in good selectivity ( 3 50%).
- the former react in the sense of vinyl derivatives to form aldehydes glycosylated in the a-position.
- the same compounds can also be obtained, for example, by adding allyl or vinyl Grignard reagents to protected glycosyl aldehydes (chemoselectively even with O-acetyl protective groups)
- the reaction of the second stage of the process creates a new chiral center at the addition site.
- the above-mentioned processes each give both diastereomers at comparable proportions. However, separation of the diastereomers at this or the subsequent stage can be avoided if asymmetric allyl silicon, allyl tin or allyl boron reagents are used However, these processes can only be used in aprotic organic solvents and therefore require the introduction of suitable protective groups in the glycoside
- the third step of the method according to the invention uses an enzymatic aldol addition to complete the transformation of the aglycone into a sugar residue.
- the aldehyde function is first generated from the synthesis equivalent introduced in the previous step and an aldol donor enzyme-catalyzed is added as a nucleophile.
- the structure of the aldol Donors should be chosen so that they match the substrate selectivity of the aldolase.
- the additions are highly diastereoselective and allow the synthesis of all diastereoisomeric oligosaccharides to be derived from this step as glycosyl ketoses and their derivatives in high chemical and optical purity
- This finding is highly surprising since the used here
- the glycosylated aldehydes are sterically extraordinarily demanding due to the large glycoside residues.
- DHAP aldolases have a wide substrate tolerance for simple and substituted aliphatic aldehydes and themselves thus also well suited for the synthesis of monosaccharides and their derivatives (cf.
- the additions are highly diastereoselective and that the oligosaccharides and their derivatives can be prepared in high chemical and optical purity. Since all four known types of DHAP aldolases can be used optionally, starting from a common one Precursors can generate all corresponding possible diastereomers in a predictable manner.
- the enzymatic aldol additions in an aqueous environment are free of protective groups under particularly mild reaction conditions at room temperature and practically neutral pH (preferably 6 8-7 0), which increases the stability of both the glycosidic bond (s) and the reaction component DHAP remain guaranteed at a sufficiently high reaction rate
- the high tolerance of the enzyme reaction can advantageously also be used in the process according to the invention for the synthesis of higher oligosaccharides (tri-, tetra-, etc.) and for the synthesis of chemically modified (typically substituted, alkylated, acylated) , acetalized) oligosaccharides with a modified activity profile
- each of the aldolases listed above preferably uses DHAP as the nucleophilic aldol donor, but a number of structurally related donors can also be used.
- the third key step according to the process of the invention can alternatively also be catalyzed by other aldolases with differing substrate specificity, which Instead of DHAP, for example, use pyruvate or phosphoenol pyruvate as the preferred donor substrate and thereby generate 2-keto acids derived from sugars with an interesting biological activity profile.
- Further aldolases use acetaldehyde or glycine for the synthesis of aldoses or a-amino-b-hydroxy acids.
- the method according to the invention can also be used to generate combinatorial oligosaccharide libraries
- the DHAP used for the synthesis is commercially available or can be produced economically, for example, by glycerol phosphate oxidase-mediated oxidation of commercial glycerol phosphate (cf. DE-4 304 097 7).
- the phosphorylated products can be easily isolated by standard processes, for example by ion exchange processes, while after phosphate ester hydrolysis ( eg catalyzed by
- DHAP aldolases with different diastereospecificity and from different organisms are commercially available (e.g. Boeh ⁇ nger Mannheim GmbH, Sandhofer Str 1 16, 68298 Mannheim, DE, Sigma Chemie GmbH, Grunwalder Weg 30,
- the compounds of the formula (I) according to the invention are useful for the inhibition and prevention of cell adhesion and cell adhesion-mediated diseases. They can be used for the treatment of inflammatory diseases, asthma, dermatitis, rheumatoid arthritis, osteoarthritis, multiple sclerosis, malignant diseases, autoimmune diseases and infections of bacterial, fungal and viral pathogens can be used
- the compounds according to the invention are valuable precursors or constituents for active pharmaceutical ingredients, in particular for the treatment of the diseases mentioned above
- a 0 5M solution of the monosaccharide in alcohol is heated under reflux for 1 5 h with an acidic ion exchanger (100 g per mol monosaccharide).
- the ion exchanger is filtered off and excess alcohol is removed in vacuo.
- the glycosid is purified by recrystallization or chromatography on silica gel
- a 0 4 M solution of the unprotected saccharide in acetic anhydride is mixed with 1% o (w / v) sodium acetate and heated to reflux for 2 h.
- the solution is poured onto 2 volumes of ice water and neutralized with solid sodium hydrogen carbonate. It is extracted three times with 2 volumes of chloroform combined organic phases are washed thoroughly with sodium bicarbonate and sodium chloride solution, dried over sodium sulfate and the solvent removed in vacuo.
- the peracetate obtained is further purified, if necessary, by recrystallization or chromatography
- the product is a mixture of free aldehyde and two diastereomeric methyl hemiacetals in a ratio of 1: 2: 2.
- AAV 7 from 12b-Ac ⁇ (18.9g).
- the product is present as a mixture of two diastereomeric methyl hemiacetals in approximately equal proportions and about 10% free aldehyde.
- AAV 7 from 13b-Ac ⁇ (9.68g).
- the product is present as a mixture of two diastereomeric methyl hemiacetals in approximately equal proportions and about 25% free aldehyde.
- a 1 M solution of the peracetylated saccharide is mixed with 1 volume of THF and 4 volumes of saturated aqueous NH ⁇ Cl solution (for solubility problems up to four times the amount of ethyl acetate and THF can be used).
- 2 to 4 equivalents of zinc dust are added and with vigorous stirring 2 to 4 equivalents of allyl bromide added dropwise over 2 h with incomplete conversion (DC
- AAV 9 (5 equivalents of 3,3-dimethylallyl bromide instead of allyl bromide) and AAV 10, from 2a-Ac 4 , 950 mg (81%).
- AAV 6 AAV 7, AAV 9 and AAV 10, from 2a, 10.0g (82% for 4 steps).
- the product corresponds to that produced according to AAV 8 from 2a-O.
- AAV 6 AAV 7, AAV 9 and AAV 10, from 3a, 7.5g (83% for 4 steps).
- the product corresponds to that produced according to AAV 8 from 3a.
- AAV 7 AAV 9 and AAV 10, from 3b-Ac 3 , 130g (68% for 3 steps).
- the product corresponds to that produced according to AAV 8 from 3b.
- 109 (2RS) -10- (methyl- ⁇ -D-glucopyranuronosyl) -4-pentene-1,2-diol (55b).
- AAV 6 AAV 7, AAV 9 and AAV 10, from 11b, 7 34g (60%)
- AAV 1 from 51a (2.64g); according to NMR mixture of free aldehyde, hydrate and diastereomeric methyl hemiacetals.
- AAV 1 from 67b (2 50g), according to the NMR mixture of free aldehyde (approx. 20%), aldehyde hydrate and diastereomeric methyl hemiacetals
- the aldehyde dissolved in some water is taken up with an aqueous solution of DHAP (80-100mM), adjusted to pH 6 8-7 3 and aldolase (FruA, RhuA or FucA, 50-150 U per 1 mmol aldehyde) is added if the conversion is incomplete DHAP and, if necessary, enzyme are added after 1 or 2 days, and the pH is checked.
- the ketose phosphate is bound to anion exchangers (HCO3 form) and with 150-200 mM Methyl ammonium bicarbonate buffer eluted The buffer is removed by concentrating in vacuo, taking up several times in water and then concentrating.
- the ketose phosphate is obtained as the sodium salt by cation exchange (sodium-loaded cation exchanger or acidic ion exchanger and neutralization with sodium hydroxide solution)
- a 20-100 mM solution of the isolated or crude ketose phosphate is adjusted to pH 75 (60) and mixed with 80-200 (20) U / mmol alkaline (acidic) phosphatase. After complete conversion (1-4 d), the mixture is activated carbon filtered and the solution (optional) desalted by filtration through an ion exchanger (HCO3 " and H form). The solution is concentrated in vacuo and the remaining syrup on silica gel, chromatographed on Ca2 + -loaded cation exchanger, on Biogel P2 or on an activated carbon / keselguhr (1/1) mixture
- AAV 12 FluA
- AAV 13 acid phosphatase
- AAV 1 1 AAV 12 (FruA) and AAV 13 (alkal phosphatase), from 59b, 130mg
- AAV 12 (FruA) and AAV 13 (alkal phosphatase), from 53b, 330mg (11%) lOld and 690mg (23%) 102d
- AAV 1 1 AAV 12 (FucA) and AAV 13 (alkal phosphatase), from 52a, 66mg
- AAV 11 AAV 12 (FucA) and AAV 13 (alkaline phosphatase); from 59b; 20mg (3%) mixture of 103b and 104b in the ratio 1: 2.
- 13 C-NMR (75.4 MHz; D 2 O): d 106.0 (C-l '), 105.49 (C-l'), 101.2 (C -2), 100.92
- AAV 12 FlucA
- AAV 13 alkaline phosphatase
- AAV 12 (FucA) and AAV 13 (alkaline phosphatase); from 53b; 372mg (12%) 103d and 62mg (2%) 104d.
- AAV 1 1 AAV 12 (RhuA) and AAV 13 (alkaline phosphatase); from 52a; 550mg (19%) 105a and 120mg (4%) 106a.
- AAV 12 (RhuA) and AAV 13 (alkaline phosphatase); from 53a; 150mg (6%) 105c and 201mg (7%) 106c
- AAV 1 1 AAV 12 (RhuA) and AAV 13 (alkal phosphatase), from 53b, 247mg (8%) 105d and 440mg (14%) 106d
- AAV 12 (FruA) and AAV 13 (alkaline phosphatase), from 26b, 154mg (45%) 108 and 109 in the ratio 6 5
- AAV 12 FluA
- AAV 13 alkal phosphatase
- AAV 1 1 AAV 12 (RhuA) and AAV 13 (alkaline phosphatase), from 68b, 130mg (18%) mixture of 113 and 114 in a ratio of 1 1
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU68242/98A AU6824298A (en) | 1997-03-11 | 1998-02-26 | Oligosaccharides and the derivatives thereof, chemo-enzymatic method for the production thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1997109787 DE19709787A1 (de) | 1997-03-11 | 1997-03-11 | Oligosaccaride und deren Derivate sowie ein chemo-enzymatisches Verfahren zu deren Herstellung |
DE19709787.1 | 1997-03-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998040390A2 true WO1998040390A2 (fr) | 1998-09-17 |
WO1998040390A3 WO1998040390A3 (fr) | 1999-01-14 |
Family
ID=7822840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/001096 WO1998040390A2 (fr) | 1997-03-11 | 1998-02-26 | Oligosaccharides et leurs derives et procede chimio-enzymatique permettant de les preparer |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6824298A (fr) |
DE (1) | DE19709787A1 (fr) |
WO (1) | WO1998040390A2 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005527467A (ja) * | 2001-08-29 | 2005-09-15 | ネオーズ テクノロジーズ, インコーポレイテッド | 新規な合成ガングリオシド誘導体およびその組成物 |
JP2006519878A (ja) * | 2003-03-06 | 2006-08-31 | ネオーズ テクノロジーズ, インコーポレイテッド | ガングリオシドの酵素合成のための方法および化合物 |
US7932236B2 (en) | 2004-11-09 | 2011-04-26 | Seneb Biosciences, Inc. | Glycolipids |
FR2999076A1 (fr) * | 2012-12-07 | 2014-06-13 | Oreal | Nouveaux composes c-xylosides carboxyles et utilisation en cosmetique. |
JP2015107941A (ja) * | 2013-12-05 | 2015-06-11 | ナガセケムテックス株式会社 | 二糖類化合物、変性オルガノポリシロキサン化合物及び界面活性剤 |
US10555959B2 (en) | 2009-03-25 | 2020-02-11 | La Jolla Pharmaceutical Company | Glycolipids as treatment for disease |
JP2020522514A (ja) * | 2017-06-05 | 2020-07-30 | フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド | マルチバイオティック剤及びその使用方法 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
EP1771066A2 (fr) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon glp-1 |
DK2586456T3 (en) | 2004-10-29 | 2016-03-21 | Ratiopharm Gmbh | Conversion and glycopegylation of fibroblast growth factor (FGF) |
ES2449195T3 (es) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Factor estimulante de colonias de granulocitos glicopegilado |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
WO2007056191A2 (fr) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Purification de sucre de nucleotide en utilisant des membranes |
US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
WO2008124406A2 (fr) | 2007-04-03 | 2008-10-16 | Neose Technologies, Inc. | Méthodes de traitement à l'aide d'un facteur g-csf glycopégylé |
EP2170919B8 (fr) | 2007-06-12 | 2016-01-20 | ratiopharm GmbH | Procédé amélioré pour la production de sucres de nucléotide |
AU2009219232B2 (en) | 2008-02-27 | 2014-02-27 | Novo Nordisk A/S | Conjugated Factor VIII molecules |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0426176A2 (fr) * | 1989-11-02 | 1991-05-08 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | 5-(alpha-D-glucopyranosyloxyméthyl)-furan-2-carboxaldehyde, ces dérivés, leurs produits en découlant et procédé pour la préparation de ces composés et leur utilisation |
-
1997
- 1997-03-11 DE DE1997109787 patent/DE19709787A1/de not_active Withdrawn
-
1998
- 1998-02-26 AU AU68242/98A patent/AU6824298A/en not_active Abandoned
- 1998-02-26 WO PCT/EP1998/001096 patent/WO1998040390A2/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0426176A2 (fr) * | 1989-11-02 | 1991-05-08 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | 5-(alpha-D-glucopyranosyloxyméthyl)-furan-2-carboxaldehyde, ces dérivés, leurs produits en découlant et procédé pour la préparation de ces composés et leur utilisation |
Non-Patent Citations (9)
Title |
---|
DE BRUYN, ANDRE ET AL: "Proton NMR study of some D-aldohexapyranosyl-D-fructos(id)es in water-d2" 1975 , BULL. SOC. CHIM. BELG. (1975), 84(8-9), 799-811 CODEN: BSCBAG XP002083667 See compounds 8,9. * |
EYRISCH, OLIVER ET AL: "Disaccharide mimetics by enzymic tandem aldol additions" 1995 , ANGEW. CHEM., INT. ED. ENGL. (1995), 34(15), 1639-41 CODEN: ACIEAY;ISSN: 0570-0833 XP002083668 siehe Seite 1639, linke Spalte, Absatz 2; Abbildung 1 siehe Seite 1639, letzte Zeile, Absatz 1 * |
KLEIN, JOACHIM ET AL: "New amphiphilic copolymers derived from hydrophobically modified vinyl saccharides" 1995 , CAN. J. CHEM. (1995), 73(11), 1941-7 CODEN: CJCHAG;ISSN: 0008-4042 XP002083661 See compound 1. * |
LICHTENTHALER, FRIEDER W. ET AL: ".alpha.-D-Glucopyranosyl-D-fructoses: distribution of furanoid and pyranoid tautomers in water, dimethyl sulfoxide, and pyridine. Studies on ketoses. Part 4" 1990 , J. CHEM. SOC., PERKIN TRANS. 2 (1990), (8), 1489-97 CODEN: JCPKBH;ISSN: 0300-9580 XP002083664 See compound c on page 1493. * |
LICHTENTHALER, FRIEDER W. ET AL: "5-(.alpha.-D-Glucosyloxymethyl)furfural: preparation from isomaltulose and exploration of its ensuing chemistry" 1993 , LIEBIGS ANN. CHEM. (1993), (9), 967-74 CODEN: LACHDL;ISSN: 0170-2041 XP002083663 See compound 6. * |
LICHTENTHALER, FRIEDER W. ET AL: "Disaccharide building blocks from isomaltulose: glucosyl-.alpha.(1.fwdarw.5)-D-arabinonic acid and ensuing products" 1993 , LIEBIGS ANN. CHEM. (1993), (9), 975-80 CODEN: LACHDL;ISSN: 0170-2041 XP002083662 See structure 1. * |
REUBEN, JACQUES: "Molecular structure as reflected in the carbon-13 NMR spectra of oligosaccharides with partially deuterated hydroxyls" 1985 , J. AM. CHEM. SOC. (1985), 107(6), 1747-55 CODEN: JACSAT;ISSN: 0002-7863 XP002083666 See fig. 2. * |
THIEM, JOACHIM ET AL: "Synthesis and reactions of leucrose and its exocyclic glycal" 1990 , CARBOHYDR. RES. (1990), 205, 333-45 CODEN: CRBRAT;ISSN: 0008-6215 XP002083946 See compound 1. * |
WAGNER, R. ET AL: "Silicon-modified carbohydrate surfactants. I. Synthesis of siloxanyl moieties containing straight-chained glycosides and amides" 1996 , APPL. ORGANOMET. CHEM. (1996), 10(6), 421-435 CODEN: AOCHEX;ISSN: 0268-2605 XP002083660 See fig. 1 (palatinose), fig. 3. * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005527467A (ja) * | 2001-08-29 | 2005-09-15 | ネオーズ テクノロジーズ, インコーポレイテッド | 新規な合成ガングリオシド誘導体およびその組成物 |
US7842677B2 (en) | 2001-08-29 | 2010-11-30 | Seneb Biosciences, Inc. | Synthetic ganglioside derivatives and compositions thereof |
JP2006519878A (ja) * | 2003-03-06 | 2006-08-31 | ネオーズ テクノロジーズ, インコーポレイテッド | ガングリオシドの酵素合成のための方法および化合物 |
US7932236B2 (en) | 2004-11-09 | 2011-04-26 | Seneb Biosciences, Inc. | Glycolipids |
US10555959B2 (en) | 2009-03-25 | 2020-02-11 | La Jolla Pharmaceutical Company | Glycolipids as treatment for disease |
FR2999076A1 (fr) * | 2012-12-07 | 2014-06-13 | Oreal | Nouveaux composes c-xylosides carboxyles et utilisation en cosmetique. |
JP2015107941A (ja) * | 2013-12-05 | 2015-06-11 | ナガセケムテックス株式会社 | 二糖類化合物、変性オルガノポリシロキサン化合物及び界面活性剤 |
WO2015083561A1 (fr) * | 2013-12-05 | 2015-06-11 | ナガセケムテックス株式会社 | Composé disaccharide, composé organopolysiloxane modifié et tensioactif |
JP2020522514A (ja) * | 2017-06-05 | 2020-07-30 | フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド | マルチバイオティック剤及びその使用方法 |
Also Published As
Publication number | Publication date |
---|---|
DE19709787A1 (de) | 1998-09-17 |
WO1998040390A3 (fr) | 1999-01-14 |
AU6824298A (en) | 1998-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998040390A2 (fr) | Oligosaccharides et leurs derives et procede chimio-enzymatique permettant de les preparer | |
Nicotra | Synthesis of C-glycosides of biological interest | |
US8703977B2 (en) | Compounds, intermediates, and methods of preparing the same | |
Verheyden et al. | Chiral syntheses of the antibiotics anisomycin and pentenomycin from carbohydrates | |
Madsen et al. | Studies related to synthesis of glycophosphatidylinositol membrane-bound protein anchors. 6. Convergent assembly of subunits | |
EP0147777A2 (fr) | Dérivés d'amides d'acides carboxyliques M-glycosylés comme produit pour combattre les maladies de type rheumatismal | |
WO2005033122A1 (fr) | Glycoside de carbonate de glycerol | |
Ermolenko et al. | Asymmetric synthesis of amino sugars. Part 2. A novel versatile approach to the chiral non-racemic synthesis of 2-amino-2-deoxy sugars. Preparation of L-glucosamine, L-mannosamine and L-talosamine derivatives | |
Sarabia-García et al. | Studies on the synthesis of tunicamycin. The preparation of 7-deoxy-2-deamino-6-hydroxy tunicamine and related products | |
Podeschwa et al. | Stereoselective synthesis of several azido/amino-and diazido/diamino-myo-inositols and their phosphates from p-benzoquinone | |
EP1001961B1 (fr) | Derives substitues du tetrahydropyrane et leur procede de production | |
Wong et al. | 2-deoxy-d-arabino-hexose, 2-deoxy-d-lyxo-hexose, and their (2R)-2-deuterio analogs | |
US5126437A (en) | Aldophosphamide glycosides, a process for their preparation and their use as pharmaceutical active compounds | |
MORI et al. | New Syntheses of 6-Deoxy-L-gulose and 6-Deoxy-L-talose | |
Zamyatina et al. | The synthesis of 1-O-(2-N-stearoyl-D-erythro-sphinganinel-phosphoryl)-2-O-(α-D-mannopyranosyl-D-myo-inositol: a fragment of the naturally occurring inositol-containing glycophosphosphingolipids | |
Rosenthal et al. | Synthesis of an analog of the nucleoside moiety of the polyoxins | |
US5126500A (en) | Preparation of retinyl glycosides and intermediates therefor | |
DE3106463C2 (de) | Verfahren zur Herstellung von Derivaten des Kanamycin A | |
KR950007250B1 (ko) | 사포닌의 제조방법 | |
EP0502298A2 (fr) | Procédé stéréosélectif pour la préparation de phosphates de beta-fucopyranose et de GDP-fucose très pur | |
DE69826394T2 (de) | Verfahren zur herstellung von c-glykosiden der ulosonsäure | |
KR930005989B1 (ko) | 인삼 사포닌의 제조방법 | |
Yamamoto et al. | Synthesis and Characterization of 5-Deoxy-3-O-methyl-5-C-[(R)-and (S)-phenylphosphinothioyl]-α-and β-d-xylopyranoses. The First Sugar Analogue Having a Phosphinothioyl Group in the Hemiacetal Ring | |
Doboszewski et al. | Synthesis of 4-Deoxy-4-C-hydroxymethyl-α-L-Lyxo-Pyranosyl Thymine | |
HAYAKAWA et al. | Introduction of an alkyl group into the sugar portion of uracilnucleosides by the use of gilman reagents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998539140 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |